Star Metro - Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform

ANN ARBOR, MI / ACCESS Newswire / March 18, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic solutions for equine and companion animals, today announced a collaboration with Boehringer Ingelheim Animal Health USA Inc., a global leader in the animal health industry, to enhance early detection along with treatment and monitoring of pituitary pars intermedia dysfunction (PPID) in horses.

The collaboration integrates the TRUFORMA system into Boehringer Ingelheim's idPPID™ awareness and testing program, enabling veterinarians to perform rapid endocrine testing at the point of care using Zomedica's equine endogenous ACTH (eACTH) and equine insulin assays.

This collaboration will now enable veterinarians to perform rapid endocrine testing at the point of care that fosters prompt diagnosis and treatment. The integration of Zomedica's TRUFORMA diagnostic platform into the Boehringer Ingelheim idPPID™ awareness and testing program brings advantages for veterinarians and horse owners, alike.

Under the agreement, Zomedica will promote the idPPID program to veterinarians within its TRUFORMA and PulseVet^® customer networks, while Boehringer Ingelheim will expand its PPID testing program to include reimbursing participating veterinarians for diagnostic testing performed with Zomedica's TRUFORMA platform and reimbursement through laboratory testing at Cornell University.

Participation in the program requires no-cost placement of TRUFORMA analyzers in equine veterinary practices along with the diagnostic cartridge kits reimbursed by Boehringer, expanding the installed base of Zomedica's platform and enabling the veterinarian to reorder both the initial cartridges and the remaining equine assays available from Zomedica, including Cortisol and Progesterone.

PPID, previously known as equine Cushing's disease, is the most common endocrine disorder in aging horses, affecting approximately 20-25% of horses over the age of 15. This prevalence has been documented in multiple epidemiological studies, including research published in the Journal of Veterinary Internal Medicine, which reported that roughly one-fifth of horses over 15 years of age show evidence of PPID based on endocrine testing (McFarlane et al., Journal of Veterinary Internal Medicine, 2018).

The program will utilize Zomedica's TRUFORMA^® equine endogenous ACTH (eACTH) assay, which recent comparative evaluation data has demonstrated to have the closest agreement to reference laboratory results when compared with other commercially available assays, supporting its reliability for diagnosing PPID and monitoring treatment response.

"Collaborating with Boehringer Ingelheim-one of the largest and most respected companies in global animal health-represents a major milestone for Zomedica," said Larry Heaton, Chief Executive Officer of Zomedica. "Their leadership in equine medicine combined with our TRUFORMA diagnostic technology creates a powerful synergy and is another critical step in our strategy.

"Veterinarians play a critical role in recognizing and managing PPID, and we've seen the meaningful difference that early diagnosis, treatment and whole-horse management can make," said Dwana Neal, Executive Director, US Equine Business at Boehringer Ingelheim. "By collaborating with Zomedica, we're expanding access to innovative diagnostic solutions and empowering veterinarians to make faster, more confident decisions-ultimately supporting better outcomes for the horses in their care, and their owners."

About Zomedica

Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet^® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi Loop^® line of therapeutic devices, along with the TRUFORMA^® diagnostic platform, TRUVIEW^® digital cytology system, VETGuardian^® no-touch monitoring system, and VETIGEL^® hemostatic gel, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. In addition, the Company offers product development services in the form of engineering services and contract manufacturing to clients in both the animal and human health markets. Headquartered in Michigan, Zomedica employs approximately 135 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 17% in 2025 to $32 million and maintains a strong balance sheet with approximately $53 million in liquidity as of December 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

About Boehringer Ingelheim 

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com. 

Follow Zomedica

• Email Alerts:http://investors.zomedica.com

• LinkedIn:https://www.linkedin.com/company/zomedica

• Facebook:https://m.facebook.com/zomedica

• Instagram:https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, including adoption of our AI technology for microscopy, and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
[email protected]
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on ACCESS Newswire

O.Ouellet--SMC